These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35858545)

  • 21. High-resolution three-dimensional NMR structure of the
    Kerkour A; Marquevielle J; Ivashchenko S; Yatsunyk LA; Mergny JL; Salgado GF
    J Biol Chem; 2017 May; 292(19):8082-8091. PubMed ID: 28330874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transposable elements (TEs) contribute to stress-related long intergenic noncoding RNAs in plants.
    Wang D; Qu Z; Yang L; Zhang Q; Liu ZH; Do T; Adelson DL; Wang ZY; Searle I; Zhu JK
    Plant J; 2017 Apr; 90(1):133-146. PubMed ID: 28106309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. More to the RAS Story: KRAS
    Lietman CD; Johnson ML; McCormick F; Lindsay CR
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35561303
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cell-type specific tumorigenesis with Ras oncogenes in human lung epithelial cells.
    Kumazaki M; Shimomura I; Kiyono T; Ochiya T; Yamamoto Y
    Biochem Biophys Res Commun; 2020 Apr; 525(2):483-490. PubMed ID: 32111352
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural Evolution of Gene Promoters Driven by Primate-Specific KRAB Zinc Finger Proteins.
    Farmiloe G; van Bree EJ; Robben SF; Janssen LJM; Mol L; Jacobs FMJ
    Genome Biol Evol; 2023 Nov; 15(11):. PubMed ID: 37847041
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells.
    Ji Z; Mei FC; Xie J; Cheng X
    J Biol Chem; 2007 May; 282(19):14048-55. PubMed ID: 17353198
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells.
    Kharbanda A; Rajabi H; Jin C; Alam M; Wong KK; Kufe D
    Oncotarget; 2014 Oct; 5(19):8893-905. PubMed ID: 25245423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models.
    Vicent S; Chen R; Sayles LC; Lin C; Walker RG; Gillespie AK; Subramanian A; Hinkle G; Yang X; Saif S; Root DE; Huff V; Hahn WC; Sweet-Cordero EA
    J Clin Invest; 2010 Nov; 120(11):3940-52. PubMed ID: 20972333
    [TBL] [Abstract][Full Text] [Related]  

  • 29. D154Q Mutation does not Alter KRAS Dimerization.
    Grozavu I; Stuart S; Lyakisheva A; Yao Z; Pathmanathan S; Ohh M; Stagljar I
    J Mol Biol; 2022 Jan; 434(2):167392. PubMed ID: 34896362
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circular RNAs are down-regulated in KRAS mutant colon cancer cells and can be transferred to exosomes.
    Dou Y; Cha DJ; Franklin JL; Higginbotham JN; Jeppesen DK; Weaver AM; Prasad N; Levy S; Coffey RJ; Patton JG; Zhang B
    Sci Rep; 2016 Nov; 6():37982. PubMed ID: 27892494
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas.
    Baldelli E; El Gazzah E; Moran JC; Hodge KA; Manojlovic Z; Bassiouni R; Carpten JD; Ludovini V; Baglivo S; Crinò L; Bianconi F; Dong T; Loffredo J; Petricoin EF; Pierobon M
    Genes (Basel); 2021 Sep; 12(9):. PubMed ID: 34573384
    [No Abstract]   [Full Text] [Related]  

  • 32. Ras effector mutant expression suggest a negative regulator inhibits lung tumor formation.
    Vandal G; Geiling B; Dankort D
    PLoS One; 2014; 9(1):e84745. PubMed ID: 24489653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism.
    Peng DH; Kundu ST; Fradette JJ; Diao L; Tong P; Byers LA; Wang J; Canales JR; Villalobos PA; Mino B; Yang Y; Minelli R; Peoples MD; Bristow CA; Heffernan TP; Carugo A; Wistuba II; Gibbons DL
    Sci Transl Med; 2019 Mar; 11(483):. PubMed ID: 30867319
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer.
    Pek M; Yatim SMJM; Chen Y; Li J; Gong M; Jiang X; Zhang F; Zheng J; Wu X; Yu Q
    Oncogene; 2017 Aug; 36(35):4975-4986. PubMed ID: 28459468
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genome-wide DNA methylation analysis of KRAS mutant cell lines.
    Tew BY; Durand JK; Bryant KL; Hayes TK; Peng S; Tran NL; Gooden GC; Buckley DN; Der CJ; Baldwin AS; Salhia B
    Sci Rep; 2020 Jun; 10(1):10149. PubMed ID: 32576853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.
    Bentley C; Jurinka SS; Kljavin NM; Vartanian S; Ramani SR; Gonzalez LC; Yu K; Modrusan Z; Du P; Bourgon R; Neve RM; Stokoe D
    Biochem J; 2013 Jun; 452(2):313-20. PubMed ID: 23496764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncogenic KRAS regulates miR-200c and miR-221/222 in a 3D-specific manner in colorectal cancer cells.
    Tsunoda T; Takashima Y; Yoshida Y; Doi K; Tanaka Y; Fujimoto T; Machida T; Ota T; Koyanagi M; Kuroki M; Sasazuki T; Shirasawa S
    Anticancer Res; 2011 Jul; 31(7):2453-9. PubMed ID: 21873159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. KRAS
    Zhou ZW; Ambrogio C; Bera AK; Li Q; Li XX; Li L; Son J; Gondi S; Li J; Campbell E; Jin H; Okoro JJ; Xu CX; Janne PA; Westover KD
    Cancer Res; 2020 Sep; 80(17):3719-3731. PubMed ID: 32605999
    [TBL] [Abstract][Full Text] [Related]  

  • 39. KRAS mutant rectal cancer cells interact with surrounding fibroblasts to deplete the extracellular matrix.
    Kim JK; Marco MR; Choi SH; Qu X; Chen CT; Elkabets M; Fairchild L; Chow O; Barriga FM; Dow LE; O'Rourke K; Szeglin B; Yarilin D; Fujisawa S; Manova-Todorova K; Paty PB; Shia J; Leslie C; Smith JJ; Lowe S; Pelossof R; Sanchez-Vega F; Garcia-Aguilar J
    Mol Oncol; 2021 Oct; 15(10):2766-2781. PubMed ID: 33817986
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.
    Ihle NT; Byers LA; Kim ES; Saintigny P; Lee JJ; Blumenschein GR; Tsao A; Liu S; Larsen JE; Wang J; Diao L; Coombes KR; Chen L; Zhang S; Abdelmelek MF; Tang X; Papadimitrakopoulou V; Minna JD; Lippman SM; Hong WK; Herbst RS; Wistuba II; Heymach JV; Powis G
    J Natl Cancer Inst; 2012 Feb; 104(3):228-39. PubMed ID: 22247021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.